Amedeo Smart

Free Medical Literature Service

 

Amedeo

HIV Infection
  Free Subscription

Articles published in
Vaccine
    May 2023
  1. CHOI Y, Lee GS, Li S, Lee JW, et al
    Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.
    Vaccine. 2023 May 11:S0264-410X(23)00524-8. doi: 10.1016/j.vaccine.2023.
    >> Share

    April 2023
  2. KOEN AL, Izu A, Baillie V, Kwatra G, et al
    Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
    Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  3. ROPER RL, Garzino-Demo A, Del Rio C, Brechot C, et al
    Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies.
    Vaccine. 2023 Apr 21:S0264-410X(23)00393-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  4. KOLAKOWSKA A, Brichler S, Delagreverie H, Marin J, et al
    Cross sectional survey of Varicella-Zoster virus and measles seropositivity in people living with HIV in a Parisian suburb and a review of current immunization guidelines.
    Vaccine. 2023 Apr 19:S0264-410X(23)00351-1. doi: 10.1016/j.vaccine.2023.
    >> Share

    March 2023
  5. WILSON GJ, Rodriguez B, Li SS, Allen M, et al
    Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
    Vaccine. 2023 Mar 17:S0264-410X(23)00262-1. doi: 10.1016/j.vaccine.2023.
    >> Share

  6. CLAY PA, Thompson TD, Markowitz LE, Ekwueme DU, et al
    Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
    Vaccine. 2023 Mar 10:S0264-410X(23)00184-6. doi: 10.1016/j.vaccine.2023.
    >> Share

  7. SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al
    Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018.
    Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023.
    >> Share

  8. GILBERT M, Ablona A, Chang HJ, Grennan T, et al
    Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver, British Columbia.
    Vaccine. 2023 Mar 7:S0264-410X(23)00229-3. doi: 10.1016/j.vaccine.2023.
    >> Share

    February 2023
  9. BAKHSHIZADEH GASHTI A, Chahal PS, Gaillet B, Garnier A, et al
    Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate.
    Vaccine. 2023 Feb 24:S0264-410X(23)00201-3. doi: 10.1016/j.vaccine.2023.
    >> Share

  10. FANTINATO FFST, Wachira VK, Porto VBG, Peixoto HM, et al
    Factors associated with yellow fever vaccine failure: A systematic literature review.
    Vaccine. 2023 Feb 23:S0264-410X(23)00133-0. doi: 10.1016/j.vaccine.2023.
    >> Share

  11. KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al
    COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
    Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023.
    >> Share

  12. FORD A, Hwang A, Mo AX, Baqar S, et al
    Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023.
    >> Share

  13. CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al
    Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study.
    Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023.
    >> Share

    January 2023
  14. STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al
    Predictors of COVID-19 vaccine uptake among people who inject drugs.
    Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.
    >> Share

    December 2022
  15. BURROWS H, Antillon M, Gauld JS, Kim JH, et al
    Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness.
    Vaccine. 2022 Dec 29:S0264-410X(22)01557-2. doi: 10.1016/j.vaccine.2022.
    >> Share

  16. ZUBKOVA I, Zhao Y, Cui Q, Kachko A, et al
    Assessing the impact of hepatitis B immune globulin (HBIG) on responses to hepatitis B vaccine during co-administration.
    Vaccine. 2022 Dec 29:S0264-410X(22)01590-0. doi: 10.1016/j.vaccine.2022.
    >> Share

  17. TRACEY G, Olivia B, Jean M, Megan H, et al
    Why does gender matter for immunization?
    Vaccine. 2022 Dec 10:S0264-410X(22)01495-5. doi: 10.1016/j.vaccine.2022.
    >> Share

    November 2022
  18. SULLIVAN KM, Farraye FA, Winthrop KL, Willer DO, et al
    Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
    Vaccine. 2022 Nov 29:S0264-410X(22)01329-9. doi: 10.1016/j.vaccine.2022.
    >> Share

  19. FIX J, Vielot NA, Lund JL, Weber DJ, et al
    Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01347.
    >> Share

  20. CAREY KA, Newman LM, Spicknall IH
    Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01291.
    >> Share

    October 2022
  21. GILLES C, Rozenberg S, Buxant F, Manigart Y, et al
    HPV genotyping in biopsies of HSIL and invasive cervical cancers in women living with HIV: A cohort- and a nested -case control study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01288.
    >> Share

  22. SHU Y, Yu Y, Ji Y, Zhang L, et al
    Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01281.
    >> Share

  23. STONER MCD, Tweedy D, Comello MGL, Toval C, et al
    Using narratives to inform the development of a digital health intervention related to COVID-19 vaccination in Black young adults in Georgia, North Carolina and Alabama.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01286.
    >> Share

  24. ODIO CD, Katzelnick LC
    'Mix and Match' vaccination: Is dengue next?
    Vaccine. 2022 Oct 1. pii: S0264-410X(22)01101.
    >> Share

    September 2022
  25. MANJATE F, Quinto L, Chirinda P, Acacio S, et al
    Impact of rotavirus vaccination on diarrheal hospitalizations in children younger than 5 years of age in a rural southern Mozambique.
    Vaccine. 2022 Sep 30. pii: S0264-410X(22)01158.
    >> Share

  26. MUES KE, Kirk B, Patel DA, Gelman A, et al
    Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01120.
    >> Share

    July 2022
  27. OSTROPOLETS A, Shoener Dunham L, Johnson KD, Liu J, et al
    Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the U.S.
    Vaccine. 2022 Jul 5. pii: S0264-410X(22)00837.
    >> Share

  28. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    >> Share

    June 2022
  29. UFFMAN EA, Li SH, Chen JL, Allen N, et al
    Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00828.
    >> Share

  30. CASAGRANDE TZ, Costa-Rocha IAD, Gavi MBRO, Miyamoto ST, et al
    Previous biological therapy and impairment of the IFN-gamma/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00703.
    >> Share

  31. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    >> Share

  32. ARAUJO BC, Simakawa R, Munhoz LG, Carmo FB, et al
    Rubella antibodies in vertically and horizontally HIV-infected young adults vaccinated early in life and response to a booster dose in those with seronegative results.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00774.
    >> Share

  33. FOLEGATTI PM, Jenkin D, Morris S, Gilbert S, et al
    Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00755.
    >> Share

  34. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    >> Share

  35. WROTNIAK BH, Garrett M, Baron S, Sojar H, et al
    Antibody dependent cell cytotoxicity is maintained by the unmutated common ancestor of 6F5, a Gp41 conformational epitope targeting antibody that utilizes heavy chain VH1-2.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00719.
    >> Share

  36. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    >> Share

    May 2022
  37. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    >> Share

  38. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    >> Share

  39. CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
    Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00590.
    >> Share

  40. CUMMINS NW, Badley AD
    Could proteasome inhibition improve therapeutic vaccine response in HIV?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00578.
    >> Share

  41. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    >> Share

  42. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    >> Share

    April 2022
  43. PERCIACCANTE A, Asensi V, Cucu AI, Charlier P, et al
    War, pandemic and vaccination - Upcoming health problems by the refugee wave in Europe?
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00465.
    >> Share

    March 2022
  44. NANTHAPISAL S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, et al
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00336.
    >> Share

  45. ISHII H, Nakamura-Hoshi M, Shu T, Matano T, et al
    Sendai virus particles carrying target virus glycoproteins for antibody induction.
    Vaccine. 2022 Mar 16. pii: S0264-410X(22)00273.
    >> Share

    February 2022
  46. QUITIAN LM, Rodriguez-Martinez CE, Sossa-Briceno MP, Cortes JA, et al
    Disease burden and vaccination priorities in Colombia.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00029.
    >> Share

  47. KOCHHAR S, Barreira D, Beattie P, Cavaleri M, et al
    Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case.
    Vaccine. 2022 Feb 11. pii: S0264-410X(21)01395.
    >> Share

    January 2022
  48. PANWAR K, Godi A, Cocuzza CE, Andrews N, et al
    Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix(R) or Gardasil(R) vaccine.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00075.
    >> Share

    December 2021
  49. RIBEIRO SP, De Moura Mattaraia VG, Almeida RR, Valentine EJG, et al
    A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01550.
    >> Share

  50. FACK C, Wood R, Hatherill M, Cobelens F, et al
    The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01488.
    >> Share

    November 2021
  51. ZOU X, He J, Zheng J, Liang M, et al
    Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01532.
    >> Share

  52. BLAIN AE, Reese HE, Marjuki H, Topaz N, et al
    Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01480.
    >> Share

    October 2021
  53. MALTEZOU HC, Panagopoulos P, Sourri F, Giannouchos TV, et al
    COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01387.
    >> Share

    September 2021
  54. KHAIMOVA R, Fischetti B, Cope R, Berkowitz L, et al
    Serological response with Heplisav-B(R) in prior Hepatitis B vaccine non-responders living with HIV.
    Vaccine. 2021 Sep 29. pii: S0264-410X(21)01251.
    >> Share

  55. LI L, Hessell AJ, Kong XP, Haigwood NL, et al
    A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.
    Vaccine. 2021;39:5607-5614.
    >> Share

    August 2021
  56. LEWIN BJ, Rodriguez J, Yang SJ, Tartof SY, et al
    Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01104.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016